1
|
Ruiz IV, Moreno D, Sole P, Gonzalez BM, Pineda E, Gaba L, Sauri T, Mileo LF, Orrillo M, Maurel J, Oliveres H, Munoz-Mateu M, Losada MV, Saez OM, Chic N, Baste N, Segarra NV, Reyes R, Prat A, Garcia-Corbacho J. 548P Molecular pre-screening using comprehensive gene panels offered by clinical trials (CT). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
2
|
Mueller V, Paplomata E, Hamilton E, Zelnak A, Fehrenbacher L, Jakobsen E, Curtit E, Boyle F, Brix E, Brenner A, Ferrario C, Munoz-Mateu M, Arkenau T, Gelmon K, Cameron D, Curigliano G, DeBusk K, Ramos J, An X, Wardley A. 275O Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.377] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
3
|
de la Haba-Rodriguez J, Morales S, Guerrero A, Martinez N, Martinez Peinado A, Anton A, Munoz-Mateu M, Garcia Saenz JA, Ramos Vazquez M, Gil Gil MJ, Margeli M, Servitja S, Bermejo B, Jurado JC, Aranda E, Casas M, Rodríguez-Martín C, Carrasco EM, Caballero R, Martin M. Bevacizumab plus Letrozol (LEA clinical trial phase III). Using hypertension for finding biomarkers of efficacy. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.2524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Juan de la Haba-Rodriguez
- Medical Oncology Department University Reina Sofia Hospital. Biomedical Research Institute Maimonides, Cordoba, Spain
| | - Serafin Morales
- Medical Oncology Department, Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain
| | | | | | | | - Antonio Anton
- Hospital Universitario Miguel Servet, Zaragoza, Spain
| | | | | | | | | | - Mireia Margeli
- Institut Català d'Oncologia - Hospital Germans Trias i Pujol, Badalona, Spain
| | - Sonia Servitja
- Medical Oncology Department. Hospital del Mar, Barcelona, Spain
| | | | | | - Enrique Aranda
- Reina Sofía Hospital, University of Córdoba, Maimonides Institute of Biomedical Research (IMIBIC). Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Córdoba, Spain
| | | | | | | | | | - Miguel Martin
- Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain
| | | |
Collapse
|
4
|
Rojo F, Lluch A, Ruiz A, Ruiz-Borrego M, Barnadas A, Calvo L, Gonzalez S, Margeli M, Rodriguez-Lescure A, Anton A, Seguí MA, Munoz-Mateu M, Dorca J, Lopez-Vega JM, Jara-Sanchez C, Martin N, Casas M, Carrasco EM, Caballero R, Martin M. Subtype analysis from the GEICAM/2003-02 study: High-risk, node-negative breast cancer patients treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.11107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Federico Rojo
- Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Ana Lluch
- Hospital Clinico Universitario de Valencia, Valencia, Spain
| | - Amparo Ruiz
- Instituto Valenciano de Oncología, Valencia, Spain
| | | | | | - Lourdes Calvo
- Complejo Hospitalario Universitario de A Coruña, A Coruna, Spain
| | | | - Mireia Margeli
- Institut Català d'Oncologia - Hospital Germans Trias i Pujol, Badalona, Spain
| | | | - Antonio Anton
- Hospital Universitario Miguel Servet, Zaragoza, Spain
| | | | | | - Joan Dorca
- Institut Catala d'Oncologia Girona, Girona, Spain
| | | | | | | | | | | | | | - Miguel Martin
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
| |
Collapse
|
5
|
Pollán M, Castello A, Ruiz A, Casas A, Baena-Cañada JM, Lope V, Antolín S, Ramos Vazquez M, Munoz-Mateu M, Lluch A, De Juan A, Jara-Sanchez C, Jimeno MA, Rosado P, Diaz Pena E, Guillem V, Carrasco EM, Perez-Gomez B, Vioque J, Martin M. Breast cancer risk among women following lifestyle recommendations: A case-control study in Spain. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.1602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Marina Pollán
- National Center of Epidemiology, Instituto Salud Carlos III, Madrid, Spain
| | - Adela Castello
- Cancer Epidemiology Unit, National Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
| | - Amparo Ruiz
- Instituto Valenciano de Oncología, Valencia, Spain
| | - Ana Casas
- Hospital Universitario Virgen Del Rocio, Sevilla, Spain
| | | | | | - Silvia Antolín
- Medical Oncology, Complejo Hospitalario Universitario a Coruña, A Coruña, Spain
| | | | | | - Ana Lluch
- Hospital Clínico de Valencia - INCLIVA Health Research Institute, University of Valencia., Valencia, Spain
| | - Ana De Juan
- Hospital Marques de Valdecilla, Santander, Spain
| | | | | | | | | | | | | | - Beatriz Perez-Gomez
- Cancer Epidemiology Unit, National Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
| | - Jesus Vioque
- Department of Public Health, Universidad Miguel Hernandez, Sant Joan D'Alacant, Spain
| | - Miguel Martin
- Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
| | | |
Collapse
|
6
|
Bermejo B, Ruiz A, Ruiz Borrego M, Ribelles N, Rodriguez-Lescure A, Munoz-Mateu M, Gonzalez S, Margeli M, Barnadas A, Ramos Vazquez M, del Barco S, Calvo L, Mendiola C, Crespo C, Rodriguez CA, Martinez E, Casas MI, Camara MC, Carrasco EM, Martin M. Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): Efficacy analysis of the GEICAM/2003-10 trial. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.1027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1027 Background: X is an active drug in metastatic breast cancer. GEICAM/2003-10 is an adjuvant trial investigating the integration of capecitabine into an epirubicin and docetaxel containing regimen for node-positive early breast cancer pts. Methods: Pts aged 18-70, with T1-T3/N1-3 operable BC were eligible. HER2+ pts were initially allowed. In October 2005, after 803 pts were included in the trial, the study was amended to exclude them. Pts were stratified by site, menopausal status, number of axillary nodes (1-3, 4-9, >9) and hormonal receptor status and randomized to receive EC (90/600 mg/m2 x4) followed by T (100 mg/m2 x4) or ET (90/75 mg/m2 x4) followed by X (1,250 mg/m2 BID, d1–14, x 4) all every three weeks. The primary endpoint was DFS. The trial was designed to detect an absolute 5-y DFS increase of 7% (72% EC-T, 79% ET-X); a sample size of 1,184 evaluable pts (592 per arm) was required to detect this difference (a=0.05, β=80%). Assuming a drop-out rate of 17%, 1,382 pts were required. The first analysis of DFS was planned after 290 events. Results: Between February 2004 and February 2007, 1384 pts (EC-T 669, ET-X 715) were randomized. Patient characteristics were balanced between arms, median age was 51, 84% of pts were HR positive and 11% HER2 positive; 66, 25 and 9% had 1-3, 4-9 and > 9 nodes respectively. The median relative dose intensity was 99% for EC, 99% for T, 99% for ET and 94% for X. The most frequent grade 3-4 toxicities (>5% in either arm) with EC-T vs. ET-X were neutropenia (19% vs. 10%) with 7% febrile neutropenia in both arms, hand-foot syndrome (2% vs. 20%), fatigue (13% vs. 11%), diarrhea (3% vs. 11%), stomatitis (6% vs. 5%) and vomiting (5% vs. 5%). After a median follow-up of 6.6 years and 292 events, the proportion of patients disease free at 5 years is 86% and 82% with EC-T and ET-X (HR for relapse 1.314, 95% CI: 1.042 – 1.657); log-rank p-value=0.0208. Overall survival was not different between treatment arms (HR 1.113, 95% CI: 0.809 – 1.531); log rank p-value=0.511. Conclusions: DFS has been in favour of EC-T in pts with node-positive early BC. Clinical trial information: NCT00129935.
Collapse
Affiliation(s)
- Begoña Bermejo
- Hospital Clinico Universitario Valencia, Valencia, Spain
| | - Amparo Ruiz
- Instituto Valenciano de Oncologia, Valencia, Spain
| | | | - Nuria Ribelles
- Hospital Universitario Virgen de la Victoria, Malaga, Spain
| | | | | | | | - Mireia Margeli
- Institut Català d'Oncologia - Hospital Germans Trias i Pujol, Barcelona, Spain
| | - Agust Barnadas
- Hospital de la Santa Creu i Sant Pau, Medical Oncology Department, Barcelona, Spain
| | | | - Sonia del Barco
- Institut Català d'Oncologia Hospital Universitari Josep Trueta, Girona, Spain
| | - Lourdes Calvo
- Complexo Hospitalario Universitario de A Coruña, A Coruna, Spain
| | | | | | | | | | | | | | | | - Miguel Martin
- Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañon, Universidad Complutense, Madrid, Spain
| | | |
Collapse
|
7
|
Martin M, Lluch A, Ruiz A, Ruiz Borrego M, Barnadas A, Gonzalez S, Calvo L, Margeli Vila M, Anton A, Rodriguez-Lescure A, Seguí-Palmer MA, Munoz-Mateu M, Dorca Ribugent J, Lopez-Vega JM, Mendiola Fernandez C, Andres R, Plazaola A, Rodriguez C, Casas MI, Carrasco EM. Randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer (BC) comparing FAC with FAC followed by weekly paclitaxel: First efficacy analysis of the GEICAM/2003-02 trial. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.1001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1001 Background: Adjuvant weekly paclitaxel (wP) sequential to anthracyclines improves the outcome of operable node-positive BC patients (pts) [Sparano NEJM 2008, Martin BCRT 2009]; however, most BC pts are currently node-negative at diagnosis. The role of wP in these pts is not well established yet. Methods: Pts aged 18-70, with T1-T3/N0 operable BC and at least one high-risk St Gallen 1998 criteria (size >2 cm, hormone-receptor [HR] negative, grade 2/3, age <35 years,) were eligible. HER2+ pts were allowed, after 792 entered the trial, the study was amended to exclude them. Pts were stratified by site, menopausal status, nodal status diagnostic method (sentinel-node biopsy versus lymphadenectomy) and HR status and randomized to receive FAC x6 (500/50/500 mg/m2 every 3w) or FAC x4→wP x8 (paclitaxel 100 mg/m2 weekly). The primary endpoint was DFS. The trial was designed to detect an absolute 5-y DFS increase of 5% (80% FAC, 85% FAC→wP); a sample size of 1812 evaluable patients (906 per arm) was required to detect this difference (α=0.05, β= 80%). Assuming a drop-out rate of 6%, 1929 pts were required. The first analysis of DFS was planned when a median follow-up of 5 years was reached. Results: Between September 2003 and October 2008, 1925 pts (FAC 974, FAC→wP 951) were randomized. Patient characteristics were well balanced between arms, median age was 50, 73% of pts were HR positive and 9% HER2 positive. 97% of pts with FAC and 85% of pts with FAC→wP completed all treatment as planned. The median dose intensity was 98% with FACx6, 99% with FACx4 and 98% with wP. The most frequent grade 3-4 toxicities (>3% in either arm) with FAC vs FAC→wP were neutropenia (25% vs 22%) with 4% vs 3% of febrile neutropenia, fatigue (3% vs 8%), sensory neuropathy (0 vs 5%), and vomiting (4% in each arm). After a median follow-up of 5.3 years, the proportion of patients disease free is 93% and 90% with FAC→wP and FAC (HR for relapse 0.732, 95% CI: 0.542 to 0.990; log-rank p-value=0.0423). Conclusions: For pts with high-risk node-negative BC, adjuvant FAC→wP was associated with a small but significant improvement in DFS compared with FAC, with manageable toxicity.
Collapse
Affiliation(s)
- Miguel Martin
- Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | | | - Amparo Ruiz
- Instituto Valenciano de Oncologia, Valencia, Spain
| | | | | | | | | | | | - Antonio Anton
- Hospital Universitario Miguel Servet, Zaragoza, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Martin M, Martinez N, Ramos M, Calvo L, Lluch A, Zamora P, Munoz-Mateu M, Caronia D, Carrasco EM, Garcia Saenz JÁ, Casado A, Chacón I, Hernando B, Ruiz-Borrego M, Gonzalez-Neira A. Randomized, phase II trial comparing continuous versus intermittent capecitabine (X) monotherapy for metastatic breast cancer (MBC): Results from the GEICAM 2009−05 study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Munoz-Mateu M, Urruticoechea A, Separovic R, Erfán J, Bachelot TD, Canon J, Kovalenko N, Staroslawska E, Pikó B, Veyret C, Pribylova O, Ciule DL, Ratnayake J, Das S, Mayne K, Ross G. Trastuzumab plus capecitabine with or without pertuzumab in patients with HER2-positive MBC whose disease has progressed during or following trastuzumab-based therapy for first-line metastatic disease: A multicenter, randomized, two-arm, phase II study (PHEREXA). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps118] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
10
|
Guirado-Risueño M, Perez Manga G, Rifa J, Perez Carrion RM, García López MJ, Velasco A, Oltra Ferrando A, Barrajon E, Lopez-Vivanco G, Munoz-Mateu M. Multicentric, observational, transversal study to describe the clinical profile of patients with metastatic breast cancer (MBC) treated with first-line bevacizumab (TRANSBREAST): Preliminary results. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1143] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|